Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,873.50p on 21-10-2026 at 08:51:14
Change 5.00p 0.27%
Buy 1,874.00p
Sell 1,873.50p
Last Trade: Buy 139.00 at 1,873.50p
Day's Volume: 618,455
Last Close: 1,868.50p
Open: 1,863.50p
ISIN: GB00BN7SWP63
Day's Range 1,856.50p - 1,873.50p
52wk Range: 1,592.00p - 2,282.00p
Market Capitalisation: £75.07b
VWAP: 1,867.3025p
Shares in Issue: 4.01b

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 139 1,873.50p Automatic Execution
09:51:14 - 21-Oct-26
Sell* 60 1,873.00p SI Trade
09:50:37 - 21-Oct-26
Buy* 6 1,874.00p SI Trade
09:50:17 - 21-Oct-26
Unknown* 4,020 1,873.50p SI Trade
09:50:07 - 21-Oct-26
Unknown* 3,047 1,873.50p SI Trade
09:50:07 - 21-Oct-26
Buy* 210 1,873.50p Automatic Execution
09:50:05 - 21-Oct-26
Buy* 302 1,873.50p Automatic Execution
09:50:05 - 21-Oct-26
Buy* 350 1,873.50p Automatic Execution
09:50:05 - 21-Oct-26
Buy* 181 1,873.50p Automatic Execution
09:50:05 - 21-Oct-26
Buy* 89 1,873.00p Automatic Execution
09:50:00 - 21-Oct-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
20th Oct 2026 (Tue) 1,870.00 1,879.50 1,855.00 1,868.50 5,286,220
19th Oct 2026 (Mon) 1,871.00 1,871.00 1,851.00 1,855.00 4,924,273
16th Oct 2026 (Fri) 1,843.00 1,870.00 1,842.50 1,862.50 12,806,361
15th Oct 2026 (Thu) 1,823.50 1,876.50 1,812.00 1,868.50 12,523,051
14th Oct 2026 (Wed) 1,740.00 1,816.00 1,740.00 1,816.00 7,626,757
13th Oct 2026 (Tue) 1,797.00 1,806.50 1,753.00 1,753.00 6,612,895
12th Oct 2026 (Mon) 1,755.00 1,771.00 1,751.00 1,771.00 3,351,693
9th Oct 2026 (Fri) 1,752.00 1,771.50 1,748.50 1,750.00 6,930,730
8th Oct 2026 (Thu) 1,773.00 1,773.00 1,735.50 1,735.50 16,330,339
7th Oct 2026 (Wed) 1,754.50 1,791.00 1,747.00 1,790.50 5,172,175
6th Oct 2026 (Tue) 1,769.50 1,786.50 1,740.50 1,765.50 5,018,567
5th Oct 2026 (Mon) 1,786.50 1,789.50 1,755.00 1,759.00 3,779,090
2nd Oct 2026 (Fri) 1,781.00 1,802.00 1,770.00 1,779.50 5,629,788
1st Oct 2026 (Thu) 1,810.50 1,830.50 1,790.50 1,795.00 8,592,563
30th Sep 2026 (Wed) 1,864.50 1,873.50 1,824.50 1,832.00 9,778,649
29th Sep 2026 (Tue) 1,866.50 1,917.00 1,852.00 1,856.00 8,485,936
28th Sep 2026 (Mon) 1,863.00 1,872.00 1,841.00 1,860.00 4,381,276
25th Sep 2026 (Fri) 1,872.00 1,891.00 1,851.00 1,851.00 6,920,309
24th Sep 2026 (Thu) 1,873.00 1,896.00 1,863.00 1,877.00 3,578,575
23rd Sep 2026 (Wed) 1,895.50 1,912.50 1,874.50 1,886.00 6,310,501
22nd Sep 2026 (Tue) 1,913.50 1,913.50 1,881.00 1,906.00 5,135,262
21st Sep 2026 (Mon) 1,878.00 1,916.00 1,868.50 1,911.00 6,861,145
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
19th Oct 2026 5:21 pm RNS Jemperli approved in MSI-H/dMMR rectal cancer
19th Oct 2026 7:00 am RNS Ris-Rez positive early data in lung cancer
15th Oct 2026 3:30 pm RNS Director/PDMR Shareholding
14th Oct 2026 3:30 pm RNS Director/PDMR Shareholding
13th Oct 2026 3:30 pm RNS Director/PDMR Shareholding
12th Oct 2026 3:30 pm RNS Director/PDMR Shareholding
8th Oct 2026 3:00 pm RNS Wendy Becker CBE - New Directorship
6th Oct 2026 3:00 pm RNS Admission to Trading
1st Oct 2026 3:00 pm RNS Total Voting Rights
24th Sep 2026 3:30 pm RNS Director/PDMR Shareholding
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

GSK wins US approval for hepatitis B drug as Hutchmed deal closes

21st Oct 2026 08:48

(Alliance News) - GSK PLC on Wednesday announced US regulatory approval for its chronic hepatitis B treatment Hibsago, while Hutchmed China Ltd confirmed the completion of a separate licensing agreement with GSK worth up to USD1.30 billion. Read More

LONDON BRIEFING: Fresnillo output down; UK backs Jackdaw drilling

21st Oct 2026 07:53

(Alliance News) - Fresnillo says it has maintained its annual production forecast, GSK has landed a US drug approval and Quilter reports its net inflows for the year have already topped 2025's level. Meanwhile, drilling at a North Sea gas field co-owned by Shell has been approved. Read More

GSK celebrates Jemperli approval in US for rectal cancer form

19th Oct 2026 18:07

(Alliance News) - GSK PLC on Monday announced an approval for Jemperli in the US for a form of locally advanced rectal cancer. Read More

GSK lung cancer treatment data shows "positive anti-tumour activity"

19th Oct 2026 08:39

(Alliance News) - GSK PLC on Monday set out its first batch of global data for the risvutatug rezetecan drug. Read More

LONDON BRIEFING: GSK hails "positive" data; Volex in record half-year

19th Oct 2026 07:57

(Alliance News) - LondonMetric reports growth in rental income over its first half, GSK posts promising results from a drug trial while Volex expects annual profit at the upper end of market forecasts. Meanwhile, Abenojar Tungsten, set to list later this month, could be worth more than GBP600 million. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,725.80
Change-7.20

Login to your account

Forgot Password?

Not Registered